Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study

被引：0
|
作者：
Zhou, F. [1 ]
Yang, L. [1 ]
Peng, J. [1 ]
Xu, H. [1 ]
Wu, H. [1 ]
Wang, Y. [1 ]
Long, X. [1 ]
Gao, Q. [2 ]
Shi, X. [3 ]
Gong, J. [4 ]
Hu, J. [3 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Dept Radiat Oncol Med Oncol, Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
[2] Huangmei Cty Peoples Hosp, Dept Radiat Oncol, Huanggang, Peoples R China
[3] Macheng Peoples Hosp, Dept Med Oncol, Macheng, Peoples R China
[4] Huangshi Cent Hosp, Dept Med Oncol, Huangshi, Hubei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
974P
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [21] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC)
    Peer, Avivit
    Neumann, Avivit
    Keizrnan, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [22] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).
    Peer, Avivit
    Neumann, Avivit
    Keizman, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial
    Ren, Chao
    Mai, Zong-Jiong
    Jin, Ying
    He, Ming-Ming
    Wang, Zhi-Qiang
    Luo, Hui-Yan
    Zhang, Dong-Sheng
    Wu, Chen-Yi
    Wang, Feng
    Xu, Rui-Hua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2946 - +
  • [24] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
    Hong, G.
    Meng, X.
    Yang, X.
    Zhang, Z. Y.
    Xia, J.
    Chen, Y-F.
    Wu, T.
    Shan, Z.
    Fan, Q.
    Wang, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S861 - S861
  • [25] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [26] Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
    Bruix, Jordi
    Tak, Won-Young
    Gasbarrini, Antonio
    Santoro, Armando
    Colombo, Massimo
    Lim, Ho-Yeong
    Mazzaferro, Vincenzo
    Wiest, Reiner
    Reig, Maria
    Wagner, Andrea
    Bolondi, Luigi
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (16) : 3412 - 3419
  • [27] HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
    Song, Yan
    Li, Ning
    Li, Qun
    Liang, Xinjun
    Zhang, Shu
    Fan, Qingxia
    Yin, Xianli
    Zhuang, Zhixiang
    Liu, Yunpeng
    Zhang, Jingdong
    Kou, Xiaoge
    Zhong, Haijun
    Wang, Xiaofei
    Dou, Yiwei
    Huang, Jing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [28] Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study
    Chang, Gee-Chen
    Tsai, Chun-Ming
    Hsia, Te-Chun
    Yang, Chih-Hsin
    Abdulnabi, Radhi
    Blair, Julie M.
    Linn, Carlos
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2013, 112 (09) : 518 - 526
  • [29] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress
    Qin, S.
    Finn, R.
    Kudo, M.
    Meyer, T.
    Vogel, A.
    Ducreux, M.
    Macarulla, T.
    Tomasello, G.
    Boisserie, F.
    Hou, J.
    Li, C.
    Song, J.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345